pipobroman has been researched along with Leukemia in 14 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 9.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 5.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 5.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 1.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| " Relapses occurred in 30% of the cases but responded to pipobroman at the initial high dosage level." | 1.26 | [Management of polycythaemia with pipobroman]. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Perreau-Boutet, MC; Stachowiak, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiladjian, JJ | 3 |
| Gardin, C | 1 |
| Renoux, M | 1 |
| Bruno, F | 1 |
| Bernard, JF | 2 |
| De Sanctis, V | 1 |
| Mazzucconi, MG | 1 |
| Spadea, A | 2 |
| Alfò, M | 1 |
| Mancini, M | 1 |
| Bizzoni, L | 1 |
| Peraino, M | 1 |
| Mandelli, F | 1 |
| Passamonti, F | 1 |
| Rumi, E | 1 |
| Malabarba, L | 1 |
| Arcaini, L | 1 |
| Orlandi, E | 1 |
| Brusamolino, E | 1 |
| Pascutto, C | 1 |
| Cazzola, M | 1 |
| Lazzarino, M | 1 |
| Rain, JD | 2 |
| Briere, J | 3 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Perreau-Boutet, MC | 1 |
| Najman, A | 1 |
| Stachowiak, J | 1 |
| Parlier, Y | 1 |
| Gorin, NC | 1 |
| Duhamel, G | 1 |
| Boivin, P | 1 |
| Barbui, T | 1 |
| Finazzi, G | 1 |
| Dupuy, E | 1 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Spadea, T | 1 |
| Latagliata, R | 1 |
| Montefusco, E | 1 |
| Cosenza, M | 1 |
| Malagnino, F | 1 |
| Pearson, TC | 1 |
| Green, AR | 1 |
| Reilly, JT | 1 |
| Harrisoni, G | 1 |
| Randi, ML | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Guilmin, F | 1 |
4 reviews available for pipobroman and Leukemia
| Article | Year |
|---|---|
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials | 2000 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
2 trials available for pipobroman and Leukemia
| Article | Year |
|---|---|
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat | 2003 |
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
8 other studies available for pipobroman and Leukemia
| Article | Year |
|---|---|
Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Disease Progression; Female; Humans; Leukemia; Ma | 2003 |
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Topics: Adult; Cause of Death; Drug Evaluation; Female; Humans; Incidence; Leukemia; Longitudinal Studies; M | 2004 |
[Management of polycythaemia with pipobroman].
Topics: Female; Humans; Leukemia; Male; Myeloproliferative Disorders; Pipobroman; Polycythemia; Polycythemia | 1982 |
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Female; Follow-Up | 1998 |
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera | 1998 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up | 2001 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |